JP2016532115A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016532115A5 JP2016532115A5 JP2016537328A JP2016537328A JP2016532115A5 JP 2016532115 A5 JP2016532115 A5 JP 2016532115A5 JP 2016537328 A JP2016537328 A JP 2016537328A JP 2016537328 A JP2016537328 A JP 2016537328A JP 2016532115 A5 JP2016532115 A5 JP 2016532115A5
- Authority
- JP
- Japan
- Prior art keywords
- sphingomyelin
- cholesteryl ester
- group
- biomarkers
- cysteine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- -1 cholesteryl ester Chemical class 0.000 claims 46
- 239000000090 biomarker Substances 0.000 claims 29
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 26
- 229960002748 norepinephrine Drugs 0.000 claims 26
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 26
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 23
- 235000018417 cysteine Nutrition 0.000 claims 23
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 20
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 claims 19
- 206010019280 Heart failures Diseases 0.000 claims 19
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 claims 16
- 235000021355 Stearic acid Nutrition 0.000 claims 15
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 15
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 15
- 239000008117 stearic acid Substances 0.000 claims 15
- 238000000034 method Methods 0.000 claims 14
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 11
- 235000021357 Behenic acid Nutrition 0.000 claims 8
- 229940116226 behenic acid Drugs 0.000 claims 8
- 235000021353 Lignoceric acid Nutrition 0.000 claims 6
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 claims 6
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 6
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 6
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 claims 6
- 229940116269 uric acid Drugs 0.000 claims 6
- YNYAYWLBAHXHLL-UHFFFAOYSA-N Normetanephrine Chemical compound COC1=CC(C(O)CN)=CC=C1O YNYAYWLBAHXHLL-UHFFFAOYSA-N 0.000 claims 5
- YNYAYWLBAHXHLL-MRVPVSSYSA-N Normetanephrine Natural products COC1=CC([C@H](O)CN)=CC=C1O YNYAYWLBAHXHLL-MRVPVSSYSA-N 0.000 claims 5
- FBWPWWWZWKPJFL-QMMMGPOBSA-N (1r)-1-(4-hydroxy-3-methoxyphenyl)ethane-1,2-diol Chemical compound COC1=CC([C@@H](O)CO)=CC=C1O FBWPWWWZWKPJFL-QMMMGPOBSA-N 0.000 claims 4
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 4
- PMMYEEVYMWASQN-IMJSIDKUSA-N trans-4-Hydroxy-L-proline Natural products O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 claims 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 102000006386 Myelin Proteins Human genes 0.000 claims 2
- 108010083674 Myelin Proteins Proteins 0.000 claims 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims 2
- 229960003067 cystine Drugs 0.000 claims 2
- 238000011156 evaluation Methods 0.000 claims 2
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 claims 2
- 210000005012 myelin Anatomy 0.000 claims 2
- 229940076788 pyruvate Drugs 0.000 claims 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 1
- 238000004590 computer program Methods 0.000 claims 1
- 229940041290 mannose Drugs 0.000 claims 1
- 229960003080 taurine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13182441 | 2013-08-30 | ||
| EP13182441.9 | 2013-08-30 | ||
| PCT/EP2014/068530 WO2015028671A1 (en) | 2013-08-30 | 2014-09-01 | Means and methods for diagnosing heart failure in a subject |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016532115A JP2016532115A (ja) | 2016-10-13 |
| JP2016532115A5 true JP2016532115A5 (enExample) | 2017-10-12 |
Family
ID=49036531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016537328A Ceased JP2016532115A (ja) | 2013-08-30 | 2014-09-01 | 被験体において心不全を診断するための手段及び方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20160209433A1 (enExample) |
| EP (1) | EP3039430A1 (enExample) |
| JP (1) | JP2016532115A (enExample) |
| CA (1) | CA2922331A1 (enExample) |
| WO (1) | WO2015028671A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012018771A2 (pt) * | 2010-01-29 | 2017-06-20 | Metanomics Gmbh | ''método para dianosticar insuficência cardíaca em um sujeito'' |
| JP2017523417A (ja) * | 2014-07-28 | 2017-08-17 | メタノミクス ゲーエムベーハー | コレステロールパラメータ、スフィンゴミエリンおよび／またはトリアシルグリセロールに基づいて心不全を診断するための手段および方法 |
| US20170285049A1 (en) * | 2014-09-01 | 2017-10-05 | Metanomics Gmbh | Means and Methods for Diagnosing Heart Failure in a Subject |
| US20180238914A1 (en) * | 2015-08-19 | 2018-08-23 | Metanomics Gmbh | Means and methods for diagnosing cardiac disease in a subject |
| KR102362234B1 (ko) * | 2016-03-09 | 2022-02-11 | 씨비메드 게엠베하 센터 포 바이오마커 리서치 인 메디슨 | 폐고혈압 (ph)의 진단을 위한 바이오마커 |
| CN115112776B (zh) * | 2021-03-18 | 2023-07-04 | 中国科学院大连化学物理研究所 | 联合标志物及在诊断心房颤动中应用及诊断试剂或试剂盒 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004059293A2 (en) * | 2002-12-24 | 2004-07-15 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
| BR112012018771A2 (pt) * | 2010-01-29 | 2017-06-20 | Metanomics Gmbh | ''método para dianosticar insuficência cardíaca em um sujeito'' |
| EP3527990A1 (en) * | 2011-07-28 | 2019-08-21 | metanomics GmbH | Use of sm_sphingomyelin (d18:1, c23:1) as a marker for heart failure |
-
2014
- 2014-09-01 JP JP2016537328A patent/JP2016532115A/ja not_active Ceased
- 2014-09-01 EP EP14759139.0A patent/EP3039430A1/en not_active Withdrawn
- 2014-09-01 CA CA2922331A patent/CA2922331A1/en not_active Abandoned
- 2014-09-01 WO PCT/EP2014/068530 patent/WO2015028671A1/en not_active Ceased
- 2014-09-01 US US14/914,815 patent/US20160209433A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016532115A5 (enExample) | ||
| Zordoky et al. | Metabolomic fingerprint of heart failure with preserved ejection fraction | |
| JP2013545988A5 (enExample) | ||
| JP2019516966A5 (enExample) | ||
| GB201107053D0 (en) | Improvements in providing image data | |
| JP2014531602A5 (enExample) | ||
| BR112014016313A2 (pt) | medições precisas de analito para tira de teste eletroquímico com base em característica(s) física(s) detectada(s) da amostra contendo o analito e parâmetros de biossensores derivados | |
| JP2015500501A5 (enExample) | ||
| EA201290711A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| WO2015126935A3 (en) | Automated profiling of the hardness of wood | |
| MX356986B (es) | Metodo para detectar aductos de nucleosomas. | |
| Beyer-Westendorf et al. | The CHA2DS2-VASc score strongly correlates with glomerular filtration rate and predicts renal function decline over time in elderly patients with atrial fibrillation and chronic kidney disease | |
| JP2017504011A5 (enExample) | ||
| CY1122360T1 (el) | Μεθοδος για τη διαγνωση της νοσου niemann-pick | |
| GB2526737A (en) | Signal processing method and apparatus | |
| BR112017009025A2 (pt) | métodos para calibrar dispositivos de computação óptica ou sensores ópticos. | |
| BR112012022014A2 (pt) | sonda indicadora de limites divisórios entre materiais | |
| BR112014014844A2 (pt) | método e dispositivo para a detecção e a análise de depósitos | |
| JP2011099666A5 (enExample) | ||
| BR112021019479A2 (pt) | Prescrição de gerenciamento de paciente remoto com base em biomarcadores | |
| CY1119797T1 (el) | Λακτοφερινη για χρηση στη διαγνωση και προγνωση της νοσου alzheimer | |
| JP2019531261A5 (enExample) | ||
| JP2014071098A5 (enExample) | ||
| WO2012139052A3 (en) | Antibody biomarkers for diabetes | |
| JP2012137087A5 (enExample) |